2024-11-19 10:24:05
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
Corporate/ 2023-07-24
Ascletis Announces Completion of 180 Pat...

--To date,approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week tr...

TIANGEN to Roll out a Stunning Automated Solution at Cell Bio 2022
Health/ 2023-07-22
TIANGEN to Roll out a Stunning Automated...

WASHINGTON,Nov. 30,2022--TIANGEN,a leading brand in the field of nucleic acid purification in China,has announced its participation in the C...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release